Navigation Links
Tianyin's Dr. James Jiayuan Tong is Invited to Speak at the CFO China Summit 2011 on January 19, 2011 at the St. Regis Hotel, Beijing
Date:11/16/2010

BEIJING, Nov. 16, 2010 /PRNewswire-Asia-FirstCall/ -- Dr. James Jiayuan Tong, Chief Financial Officer, Chief Business & Development Officer and Director of Tianyin Pharmaceutical (NYSE Amex: TPI) is invited to present at CFO China Summit 2011 which will be held at the St. Regis Hotel at 21 Jianguomenwai Avenue, Beijing 100020, China on January 19, 2011.

Dr. Tong will present in two panel discussions:

  1. Implementing Effective Working Capital Management Strategies in China at 11:15 am
  2. Understanding How CFOs in China Can Raise Funds through the Capital Markets at 12:00 noon

About the CFO China Summit 2011

The CFO China Summit 2011, held in Beijing on January 19th, 2011, is part of the successful CFO Asia Summit series that gathers leading financial drivers in China's economy to discuss key challenges currently faced by CFOs in China. Supported by the Wall Street Journal, this summit draws the top financial minds to discuss the core financial and organizational issues and develop effective strategies and solutions. The Summit will be held in a panel discussion format in order to ensure maximum engagement and interaction amongst the speakers and delegates, for enhanced idea generation and sharing of experiences gathered from their day-to-day work.

Key themes for the CFO China Summit 2011:

  1. Financial risk management – Formulating strategies to minimize investment risks and generate higher returns on investments;
  2. Working capital management – Ensuring healthy cash flow to finance growth in the business;
  3. Talent management – Strategies to attract, train and retain qualified talent in the finance team;
  4. Standardization of operating procedures in the finance function;
  5. Ensuring sustainable growth amidst economic uncertainties – Developing approaches to buffer the changing economic policies for enhanced organizational stability.

More information regarding the Summit can be found on www.CFO-ChinaSummit.com

About Tianyin Pharmaceutical

Tianyin Pharmaceutical Co., Inc., headquartered at Chengdu, China, specializes in the development, manufacturing, marketing and sale of patented biopharmaceutical, modernized traditional Chinese medicines, branded generics and other pharmaceuticals. Tianyin currently manufactures and markets a comprehensive portfolio of 56 products, 23 of which are listed in the highly selective National Reimbursement List, 7 are included in the Essential Drug List of China. Tianyin has a pipeline of 10 products pending SFDA approval targeting cardiovascular conditions, women's health, immune system and respiratory disorders. Tianyin has an extensive nationwide distribution network with 730 sales representatives out of totaled 1,365 employees. For more information about Tianyin, please visit http://www.tianyinpharma.com.

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.For more information, please contact:Investors Contact:James Jiayuan Tong M.D. Ph.D.Chief Financial Officer, Chief Business & Development OfficerDirectorTianyin Pharmaceutical Co., Inc. Web:   http://www.tianyinpharma.com Email: Dr.Tong@tianyinpharma.com Tel:
+86-28-8551-6696 (Chengdu, China)+1-949-350-6999 (U.S.)+86-134 36 550011 (China)Address:23rd Floor Unionsun Yangkuo PlazaNo. 2, Block 3, South Renmin RoadChengdu, 610041China
'/>"/>

SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. James L. Wittliff, Ph.D., FACB, to Present Predicting Breast Cancer Outcome with Gene Expression Signatures on the Ziplex(R) System at the Association for Molecular Pathology Conference, October 30
2. Cerimon Pharmaceuticals Appoints James S. Shannon, M.D., to Board of Directors
3. Kendle to Present at the 2008 Raymond James Boston Fall Investors Conference
4. Kendle to Present at Upcoming Barclays Capital and Raymond James Conferences
5. Dr. James Cai Joins aTyr Pharma to Drive Clinical Development in Asia
6. Professors Raphael Haftka and C. T. Sun to receive AIAA-ASC James H. Starnes, Jr. Award
7. Professors Raphael Haftka and C. T. Sun to receive AIAA-ASC James H. Starnes Jr. Award
8. Hollis-Eden Pharmaceuticals Announces Appointment of Dr. James M. Frincke President and CEO
9. Former Secretary of Veterans Affairs James Peake to Join the Cellphire Board of Directors
10. Microfluidics Chairman James N. Little, Ph.D., Announces Retirement from Board of Directors
11. Rensselaer Polytechnic Institute professor James Lu garners award for research on 3-D computer chips
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Feb. 24, 2017 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced its unaudited financial results for the third quarter ... December 31, 2016. Third Quarter of Fiscal ... quarter of fiscal 2017 increased by 18.6% to RMB200.9 ...
(Date:2/24/2017)... -- VWR Corporation (NASDAQ: VWR), the leading global independent provider of ... reported its financial results for the fourth quarter and full ... 4Q16 record quarterly net sales of $1.13 billion, ... 4Q16 EMEA-APAC segment net sales ... Americas net sales increased 2.5%, or down 0.9% on an ...
(Date:2/23/2017)... RAFAEL, Calif., Feb. 23, 2017 ... U.S. dollars, except per share data, unaudited)Three Months Ended ... ChangeTotal BioMarin Revenue $   ...   22832%$ 1,117$   89026%Aldurazyme Net Product Revenue ... 906538%34823946%Naglazyme Net Product Revenue  ...
(Date:2/23/2017)... JOSE, Calif. , Feb. 23, 2017 /PRNewswire/ ... exclusive license for two key immunotherapy technologies from ... first technology provides a method to monitor a ... such as PD-L1 and CTLA-4.  The second license ... if a patient is likely to have an ...
Breaking Biology Technology:
(Date:2/3/2017)... SAN ANTONIO , Feb. 3, 2017  Texas Biomedical ... Dr. Larry Schlesinger as the Institute,s ... of Texas Biomed effective May 31, 2017. He is currently ... and Director of the Center for Microbial Interface Biology at ... Dr. Schlesinger as the new President and CEO of Texas ...
(Date:2/2/2017)... 2, 2017  EyeLock LLC, a market leader of ... paper " What You Should Know About Biometrics in ... user authenticity is a growing concern. In traditional schemes, ... However, traditional authentication schemes such as username/password suffer from ... authentication offers an elegant solution to the problem of ...
(Date:1/31/2017)... Mass. , Jan. 31, 2017  Spero ... novel therapies for the treatment of bacterial infections, ... set of antibacterial candidates from Pro Bono Bio ... increased prevalence of multi-drug resistant forms of Gram-negative ... Cantab Anti Infectives Ltd, a PBB group company. ...
Breaking Biology News(10 mins):